FMP
MyMD Pharmaceuticals, Inc.
MYMD
NASDAQ
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
2.27 USD
-0.13 (-5.73%)
About
ceo
Dr. Christopher C. Chapman Jr., M.D.
sector
Healthcare
industry
Biotechnology
website
https://www.mymd.com
exchange
NASDAQ
Description
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
CIK
0001321834
ISIN
US62856X2018
CUSIP
00973E409
Address
855 North Wolfe Street
Phone
856 848 8698
Country
US
Employee
6
IPO Date
Jan 23, 2014
Key Executives
